EARNINGS: Gilead reported a miss on both EPS and revenue, despite progress on its coronavirus treatment remdesivir.
Like all ChartIQ markers, the object itself is managed by the chart, so when you scroll the chart the object moves with you. It is also destroyed automatically for you when the symbol is changed.
Like all ChartIQ markers, the object itself is managed by the chart, so when you scroll the chart the object moves with you. It is also destroyed automatically for you when the symbol is changed.Like all ChartIQ markers, the object itself is managed by the chart, so when you scroll the chart the object moves with you. It is also destroyed automatically for you when the symbol is changed.Volume
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Gilead Sciences sales fall 10% as drug demand falls due to coronavirus pandemic
Weiterlesen »
Gilead Sciences sales fall 10% as drug demand falls due to coronavirus pandemic
Weiterlesen »
Tread carefully—is there life on Mars?How do you search for life on Mars? On 'Babbage', alokjha speaks to leading scientists about the instruments they hope will reveal life on Earth’s nearest neighbour
Weiterlesen »
Mike Santoli's market notes: Fed impact, more risk-embracing tone, 2009 vs. 1929New for subscribers: Mike Santoli's market notes: Fed impact, more risk-embracing tone, 2009 vs. 1929 Check out CNBCPro for a free trial.
Weiterlesen »
Tech Antitrust Hearing Puts Big Data on Hot SeatCongressional lawmakers peppered the chief executives of Alphabet Inc., Facebook Inc., Amazon.com Inc. and Apple Inc. with questions about their respective companies’ footprints and allegations of anticompetitive behavior.
Weiterlesen »
Kodak soars another 60% after Trump announces deal to manufacture generic drug ingredientsKodak soared on Tuesday after President Donald Trump announced a deal to work with the photography pioneer to produce ingredients in generic drugs.
Weiterlesen »